Cyclacel Pharms

CYCC NASDAQ
0.6350
-0.0550
-7.97%
盘后: 0.6400 +0.013 +2.07% 16:00 05/20 EDT
开盘
0.6720
昨收
0.6900
最高
0.7200
最低
0.6100
成交量
7.25万
成交均量(3M)
76.62万
52周最高
1.870
52周最低
0.5100
换手率
0.42%
市值
1,092.21万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Cyclacel Pharms CYCC股票价格,Cyclacel Pharms股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开 >

最近浏览

名称
价格
涨跌幅